Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIM-TD: Deutetrabenazine Long-Term Safety in Tardive Dyskinesia
NCT02198794Phase 3Completed
- Sponsor
- Auspex Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of deutetrabenazine in tardive dyskinesia (TD), sponsored by Auspex Pharmaceuticals. Started Oct 2014; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT02198794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198794.